Novel therapeutic approaches in utilizing platelet lysate in regenerative medicine: Are we ready for clinical use?

J Cell Physiol. 2019 Aug;234(10):17172-17186. doi: 10.1002/jcp.28496. Epub 2019 Mar 25.

Abstract

Hemoderivative materials are used to treat different diseases. These derivatives include platelet-rich plasma, serum, platelet gel, and platelet lysate (PL). Among them, PL contains more growth factors than the others and its production is inexpensive and easy. PL is one of the proper sources of platelet release factors. It is used in cells growth and proliferation and is a good alternative to fetal bovine serum. In recent years, the clinical use of PL has gained more appeal by scientists. PL is a solution saturated by growth factors, proteins, cytokines, and chemokines and is administered to treat different diseases such as wound healing, bone regeneration, alopecia, oral mucositis, radicular pain, osteoarthritis, and ocular diseases. In addition, it can be used in cell culture for cell therapy and tissue transplantation purposes. Platelet-derived growth factor, fibroblast growth factor, insulin-like growth factor, transforming growth factor β, and vascular endothelial growth factor are key PL growth factors playing a major role in cell proliferation, wound healing, and angiogenesis. In this paper, we scrutinized recent advances in using PL and PL-derived growth factors to treat diseases and in regenerative medicine, and the ability to replace PL with other hemoderivative materials.

Keywords: autologous platelet lysate; growth factors; platelet lysate; regenerative medicine; tissue engineering.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Blood Platelets / metabolism*
  • Humans
  • Intercellular Signaling Peptides and Proteins / metabolism*
  • Regenerative Medicine / methods*

Substances

  • Intercellular Signaling Peptides and Proteins